Journal of Integrative Oncology

ISSN: 2329-6771

Open Access

Edward Takes

Research Institute in Healthcare Science, California, USA

  • Mini Review   
    Editorial on Cancer Immunotherapy's Multidimensional Biomarker Landscape
    Author(s): Edward Takes*

    Late advances in the field of immuno-oncology have prompted a change in perspective in the norm of care for human tumors. A superior comprehension of resistant observation wherein inborn safe cells kill disease cells, combined with the disclosure of T-cell invulnerable designated spot inhibitors (ICIs), have essentially further developed endurance results and personal satisfaction for some patients. Immunizer barricade of resistant designated spots Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) and Programmed cell Death 1 (PD1)/PD1 ligand 1 (PD-L1) have been displayed to reestablish antitumor invulnerability in various growth types, for example, melanoma, renal cell carcinoma, non-little cell lung carcinoma and Hodgkin's lymphoma. Nonetheless, as more growth types exhibiting likely advantage to ICIs are noted, strong reactions are noticed exclusively in little subse.. Read More»
    DOI: 10.37421/2329-6771.2022.11.387

    Abstract HTML PDF

arrow_upward arrow_upward